Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects (CT02)

This study has been completed.
Information provided by (Responsible Party):
CERESPIR Identifier:
First received: September 15, 2010
Last updated: February 9, 2015
Last verified: February 2015

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CHF5074 in young healthy male volunteers.

Condition Intervention Phase
Alzheimer's Disease
Drug: CHF5074 1x
Drug: CHF5074 2x
Drug: CHF5074 3x
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

Resource links provided by NLM:

Further study details as provided by CERESPIR:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: from Screening through Day 18 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Dose linearity of CHF5074 plasma levels (Cmax) [ Time Frame: Day -1 through Day 18 ] [ Designated as safety issue: No ]
  • Dose linearity of CHF5074 plasma levels (AUC 0-t) [ Time Frame: Day -1 through Day 18 ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: September 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CHF5074 1x
oral tablet, multidose
Drug: CHF5074 1x
oral tablet, 1x, once a day in the morning for 14 days
Experimental: CHF5074 2x
oral tablet, multidose
Drug: CHF5074 2x
oral tablet, 2x, once a day in the morning for 14 days
Experimental: CHF5074 3x
oral tablet, multidose
Drug: CHF5074 3x
oral tablet, 3x, once a day in the morning for 14 days
Placebo Comparator: Placebo
placebo, oral tablet, multidose
Drug: Placebo
oral tablet, placebo, once a day in the morning for 14 days


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is judged to be in good health on the basis of medical history, complete physical examination including vital signs, 12-lead electrocardiogram (ECG) and standard laboratory tests.

Exclusion Criteria:

  • Medical history (within the last 10 years) of major cardiovascular, hepatic or renal disease.
  • Abnormal results of liver function tests, renal function tests or thyroid tests performed at screening.
  • Significant allergic conditions that require medical treatment
  • Use of any psychoactive, recreational or prescription drug within the 4 weeks prior to study drug administration.
  • Use of ibuprofen, sulindac sulfide, indomethacin, flurbiprofen within 2 weeks prior to study drug administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01203384

United States, New Jersey
Iberica Clinical Research Center
Eatontown, New Jersey, United States, 07724
Sponsors and Collaborators
Principal Investigator: Magdy L Shenouda, MD Iberica Clinical Research Center
  More Information

No publications provided

Responsible Party: CERESPIR Identifier: NCT01203384     History of Changes
Other Study ID Numbers: CCD-0913-PR-0038
Study First Received: September 15, 2010
Last Updated: February 9, 2015
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies processed this record on February 26, 2015